Risk–benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis

Publisher： John Wiley & Sons Inc

E-ISSN： 1742-1241|69|4|436-443

ISSN： 1368-5031

Source： INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol.69, Iss.4, 2015-04, pp. : 436-443

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase-5 Inhibitors Could Be Efficacious in the Treatment of Erectile Dysfunction after Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis

By  

Urologia Internationalis, Vol. 90, Iss. 3, 2012-12 ,pp. : 339-347

Karger

Access to resources Recommend Favorite

Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis

By  

Urologia Internationalis, Vol. 98, Iss. 2, 2016-08 ,pp. : 198-204

Karger

Access to resources Recommend Favorite

Update on the Use of Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction

By  

Current Urology, Vol. 2, Iss. 3, 2009-01 ,pp. : 113-121

Karger

Access to resources Recommend Favorite

Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

By Axilrod Andrew C.  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3189-3198

Informa Healthcare

Access to resources Recommend Favorite

Oral Treatment of Erectile Dysfunction with Apomorphine SL

By  

Urologia Internationalis, Vol. 67, Iss. 4, 2001-12 ,pp. : 257-263

Karger

Access to resources Recommend Favorite